Hemay Pharmaceutical Nets Nearly CNY 300 Mn in Series D

Hemay Pharmaceutical (Chinese: 和美药业) announced that it had completed a nearly CNY 300 million Series D funding round, which was led by HongFu Investment (Chinese: 鸿富资产), followed by JiHan Capital (Chinese: 吉瀚投资), FaKong Industrial Investment (Chinese: 发控产投), TaiKun Capital (Chinese: 泰鲲投资), and Anxin Guosheng Weixin Fund (Chinese: 安信国生微芯基金). TriRiver Capital acted as the exclusive financial adviser (Chinese: 三江资本). Before this round, Hemay Pharmaceutical has raised nearly CNY 1 billion from famous companies such as Legend Capital (Chinese: 君联资本), Cenova (Chinese: 千骥资本), Truman, TaiGe Capital (Chinese: 泰格投资), Efung Capital (Chinese: 倚锋资本), ZWisdom (Chinese: 真灼资本), and DeTong Capital (Chinese: 德同资本).   

Proceeds will be mainly used to accelerate the clinical trials of multiple pipelines and indications, the registration of new drugs, the business layout, and the implementation of industrialization.

Founded in 2019, Hemay Pharmaceutical is a developer of innovative drugs intended to provide more effective, safer and more economical new drugs. The company researches and develops new drugs to cure tumor and immune diseases such as breast cancer, Non-small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), psoriasis and Inflammatory bowel disease, enabling patients to get better treatments. Now the company has two classes and three indications entering into Phase III clinical trial. Hemay005 in the treatment of Behçet disease has received ODD from FDA, and it has already finished the core Phase III clinical trial for the treatment of psoriasis.

Hemay Pharmaceutical's competitors include Henlius (Chinese: 复宏汉霖), Simcere (Chinese: 先声药业), and ChiaTai TianQing (Chinese: 正大天晴).